GUIDANCE ON MONITORING AND MANAGEMENT OF ADVERSE EVENTS AND DOSE MODIFICATIONS WITH RIBOCICLIB TREATMENT BASED ON RESULTS FROM THE MONALEESA PROGRAM

347

  • Hronek, Jan MSN, ACNP, AOCNP®

  • Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN

Oncology Nursing Forum 46(2):p 186, March 2019.
Copyright © 2019 Oncology Nursing Society